In Vivo Approaches to Generate CAR T Cells Engineered to Mediate Durable Antitumor Responses

Time: 11:30 am
day: Day Two


• Autologous CAR T cell products have been transformational in hematological malignancies however manufacturing complexities limit patient access
• Umoja’s VivoVec off-the-shelf lentiviral vector platform enables efficient generation of functional CAR T cells in vivo
• Applying these approaches to target both hematological and solid tumor cancers